Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?
Background More and more patients with multiple sclerosis (MS) switch from natalizumab to fingolimod because of the risk of progressive multifocal leukoencephalopathy. The duration of the treatment holiday is still under debate referring to a possible recurrence of disease activity. Aim of the study...
Gespeichert in:
| Veröffentlicht in: | Acta neurologica Scandinavica 2014-03, Vol.129 (3), p.e12-e15 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e15 |
|---|---|
| container_issue | 3 |
| container_start_page | e12 |
| container_title | Acta neurologica Scandinavica |
| container_volume | 129 |
| creator | Wipfler, P. Harrer, A. Pilz, G. Oppermann, K. Afazel, S. Haschke-Becher, E. Sellner, J. Trinka, E. Kraus, J. |
| description | Background
More and more patients with multiple sclerosis (MS) switch from natalizumab to fingolimod because of the risk of progressive multifocal leukoencephalopathy. The duration of the treatment holiday is still under debate referring to a possible recurrence of disease activity.
Aim of the study
The aim of this study was to evaluate the prognostic value of natalizumab saturation on T cells for the recurrence of clinical and radiological disease activity.
Methods
Cell surface‐bound natalizumab saturation (in%) of CD8+ and CD4+ T cells from five patients with MS was determined before initiation of fingolimod by flow cytometry and related to clinical and MRI outcome during a 6‐month follow‐up.
Results
In two patients with either clinical or radiological disease activity, the natalizumab saturation on CD8+ and CD4+ T cells was |
| doi_str_mv | 10.1111/ane.12182 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1500761539</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3192168921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4592-454ce707e59330fe2d8d3674bb0e10aa225c689fe61bc5d74224b7d5c8ecbd503</originalsourceid><addsrcrecordid>eNqFkdtLHDEUh0Op6Gp96D9QBvqiD6Mnt8lOX0TEGywr9IJ9SzOTMxg7F00yrutfb3RVSqE0LycHvvORnB8hHyns0XT2TY97lNEpe0cmtADIQYB4TyYAQPOCU7FBNkO4Th1TQqyTDSaAM8mLCfk1N9G07mHsTJUFE0dvohv6L1nlhs743-izZvCZ6627c3Y0bRY9mthhH7OroXXWLDPTxIT1f4gWLl5ZbxamPfhA1hrTBtx-qVvkx8nx96OzfHZxen50OMtrIUuWCylqVKBQlpxDg8xOLS-UqCpACsYwJutiWjZY0KqWVgnGRKWsrKdYV1YC3yI7K--NH25HDFF3LtTYtmk5wxg0lQCqoJKX_0dFyRQtBdCEfv4LvR5G36ePPFE0vVU9U7srqvZDCB4bfeNd2t5SU9BPCelk1s8JJfbTi3GsOrRv5GskCdhfAQvX4vLfJn04P35V5qsJFyLev02k9HShuJL6cn6qv17-nJ2xdPnGHwG_UamG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1491933701</pqid></control><display><type>article</type><title>Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wipfler, P. ; Harrer, A. ; Pilz, G. ; Oppermann, K. ; Afazel, S. ; Haschke-Becher, E. ; Sellner, J. ; Trinka, E. ; Kraus, J.</creator><creatorcontrib>Wipfler, P. ; Harrer, A. ; Pilz, G. ; Oppermann, K. ; Afazel, S. ; Haschke-Becher, E. ; Sellner, J. ; Trinka, E. ; Kraus, J.</creatorcontrib><description>Background
More and more patients with multiple sclerosis (MS) switch from natalizumab to fingolimod because of the risk of progressive multifocal leukoencephalopathy. The duration of the treatment holiday is still under debate referring to a possible recurrence of disease activity.
Aim of the study
The aim of this study was to evaluate the prognostic value of natalizumab saturation on T cells for the recurrence of clinical and radiological disease activity.
Methods
Cell surface‐bound natalizumab saturation (in%) of CD8+ and CD4+ T cells from five patients with MS was determined before initiation of fingolimod by flow cytometry and related to clinical and MRI outcome during a 6‐month follow‐up.
Results
In two patients with either clinical or radiological disease activity, the natalizumab saturation on CD8+ and CD4+ T cells was <30%. In contrast, the remaining three patients with absence of disease activity had a median natalizumab saturation of 70% (range 59–79%) on CD4+ and 66% (range 52–68%) on CD8+ T cells.
Conclusions
The data of this pilot study indicate that clinical and radiological disease activity is closely linked to natalizumab saturation at the time point of switch. The determination of natalizumab saturation may be an essential tool to monitor cessation of natalizumab treatment.</description><identifier>ISSN: 0001-6314</identifier><identifier>EISSN: 1600-0404</identifier><identifier>DOI: 10.1111/ane.12182</identifier><identifier>PMID: 24032536</identifier><identifier>CODEN: ANRSAS</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - metabolism ; biomarker ; CD4 antigen ; Female ; fingolimod ; Fingolimod Hydrochloride ; Humans ; Immunosuppressive Agents - therapeutic use ; Lymphocytes ; Magnetic Resonance Imaging ; Male ; Medical research ; Middle Aged ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Multiple Sclerosis, Relapsing-Remitting - pathology ; Natalizumab ; natalizumab saturation ; Propylene Glycols - therapeutic use ; Sphingosine - analogs & derivatives ; Sphingosine - therapeutic use ; Time Factors ; treatment holiday</subject><ispartof>Acta neurologica Scandinavica, 2014-03, Vol.129 (3), p.e12-e15</ispartof><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4592-454ce707e59330fe2d8d3674bb0e10aa225c689fe61bc5d74224b7d5c8ecbd503</citedby><cites>FETCH-LOGICAL-c4592-454ce707e59330fe2d8d3674bb0e10aa225c689fe61bc5d74224b7d5c8ecbd503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fane.12182$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fane.12182$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27911,27912,45561,45562</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24032536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wipfler, P.</creatorcontrib><creatorcontrib>Harrer, A.</creatorcontrib><creatorcontrib>Pilz, G.</creatorcontrib><creatorcontrib>Oppermann, K.</creatorcontrib><creatorcontrib>Afazel, S.</creatorcontrib><creatorcontrib>Haschke-Becher, E.</creatorcontrib><creatorcontrib>Sellner, J.</creatorcontrib><creatorcontrib>Trinka, E.</creatorcontrib><creatorcontrib>Kraus, J.</creatorcontrib><title>Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?</title><title>Acta neurologica Scandinavica</title><addtitle>Acta Neurol Scand</addtitle><description>Background
More and more patients with multiple sclerosis (MS) switch from natalizumab to fingolimod because of the risk of progressive multifocal leukoencephalopathy. The duration of the treatment holiday is still under debate referring to a possible recurrence of disease activity.
Aim of the study
The aim of this study was to evaluate the prognostic value of natalizumab saturation on T cells for the recurrence of clinical and radiological disease activity.
Methods
Cell surface‐bound natalizumab saturation (in%) of CD8+ and CD4+ T cells from five patients with MS was determined before initiation of fingolimod by flow cytometry and related to clinical and MRI outcome during a 6‐month follow‐up.
Results
In two patients with either clinical or radiological disease activity, the natalizumab saturation on CD8+ and CD4+ T cells was <30%. In contrast, the remaining three patients with absence of disease activity had a median natalizumab saturation of 70% (range 59–79%) on CD4+ and 66% (range 52–68%) on CD8+ T cells.
Conclusions
The data of this pilot study indicate that clinical and radiological disease activity is closely linked to natalizumab saturation at the time point of switch. The determination of natalizumab saturation may be an essential tool to monitor cessation of natalizumab treatment.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - metabolism</subject><subject>biomarker</subject><subject>CD4 antigen</subject><subject>Female</subject><subject>fingolimod</subject><subject>Fingolimod Hydrochloride</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Lymphocytes</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Multiple Sclerosis, Relapsing-Remitting - pathology</subject><subject>Natalizumab</subject><subject>natalizumab saturation</subject><subject>Propylene Glycols - therapeutic use</subject><subject>Sphingosine - analogs & derivatives</subject><subject>Sphingosine - therapeutic use</subject><subject>Time Factors</subject><subject>treatment holiday</subject><issn>0001-6314</issn><issn>1600-0404</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkdtLHDEUh0Op6Gp96D9QBvqiD6Mnt8lOX0TEGywr9IJ9SzOTMxg7F00yrutfb3RVSqE0LycHvvORnB8hHyns0XT2TY97lNEpe0cmtADIQYB4TyYAQPOCU7FBNkO4Th1TQqyTDSaAM8mLCfk1N9G07mHsTJUFE0dvohv6L1nlhs743-izZvCZ6627c3Y0bRY9mthhH7OroXXWLDPTxIT1f4gWLl5ZbxamPfhA1hrTBtx-qVvkx8nx96OzfHZxen50OMtrIUuWCylqVKBQlpxDg8xOLS-UqCpACsYwJutiWjZY0KqWVgnGRKWsrKdYV1YC3yI7K--NH25HDFF3LtTYtmk5wxg0lQCqoJKX_0dFyRQtBdCEfv4LvR5G36ePPFE0vVU9U7srqvZDCB4bfeNd2t5SU9BPCelk1s8JJfbTi3GsOrRv5GskCdhfAQvX4vLfJn04P35V5qsJFyLev02k9HShuJL6cn6qv17-nJ2xdPnGHwG_UamG</recordid><startdate>201403</startdate><enddate>201403</enddate><creator>Wipfler, P.</creator><creator>Harrer, A.</creator><creator>Pilz, G.</creator><creator>Oppermann, K.</creator><creator>Afazel, S.</creator><creator>Haschke-Becher, E.</creator><creator>Sellner, J.</creator><creator>Trinka, E.</creator><creator>Kraus, J.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201403</creationdate><title>Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?</title><author>Wipfler, P. ; Harrer, A. ; Pilz, G. ; Oppermann, K. ; Afazel, S. ; Haschke-Becher, E. ; Sellner, J. ; Trinka, E. ; Kraus, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4592-454ce707e59330fe2d8d3674bb0e10aa225c689fe61bc5d74224b7d5c8ecbd503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - metabolism</topic><topic>biomarker</topic><topic>CD4 antigen</topic><topic>Female</topic><topic>fingolimod</topic><topic>Fingolimod Hydrochloride</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Lymphocytes</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Multiple Sclerosis, Relapsing-Remitting - pathology</topic><topic>Natalizumab</topic><topic>natalizumab saturation</topic><topic>Propylene Glycols - therapeutic use</topic><topic>Sphingosine - analogs & derivatives</topic><topic>Sphingosine - therapeutic use</topic><topic>Time Factors</topic><topic>treatment holiday</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wipfler, P.</creatorcontrib><creatorcontrib>Harrer, A.</creatorcontrib><creatorcontrib>Pilz, G.</creatorcontrib><creatorcontrib>Oppermann, K.</creatorcontrib><creatorcontrib>Afazel, S.</creatorcontrib><creatorcontrib>Haschke-Becher, E.</creatorcontrib><creatorcontrib>Sellner, J.</creatorcontrib><creatorcontrib>Trinka, E.</creatorcontrib><creatorcontrib>Kraus, J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Acta neurologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wipfler, P.</au><au>Harrer, A.</au><au>Pilz, G.</au><au>Oppermann, K.</au><au>Afazel, S.</au><au>Haschke-Becher, E.</au><au>Sellner, J.</au><au>Trinka, E.</au><au>Kraus, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?</atitle><jtitle>Acta neurologica Scandinavica</jtitle><addtitle>Acta Neurol Scand</addtitle><date>2014-03</date><risdate>2014</risdate><volume>129</volume><issue>3</issue><spage>e12</spage><epage>e15</epage><pages>e12-e15</pages><issn>0001-6314</issn><eissn>1600-0404</eissn><coden>ANRSAS</coden><abstract>Background
More and more patients with multiple sclerosis (MS) switch from natalizumab to fingolimod because of the risk of progressive multifocal leukoencephalopathy. The duration of the treatment holiday is still under debate referring to a possible recurrence of disease activity.
Aim of the study
The aim of this study was to evaluate the prognostic value of natalizumab saturation on T cells for the recurrence of clinical and radiological disease activity.
Methods
Cell surface‐bound natalizumab saturation (in%) of CD8+ and CD4+ T cells from five patients with MS was determined before initiation of fingolimod by flow cytometry and related to clinical and MRI outcome during a 6‐month follow‐up.
Results
In two patients with either clinical or radiological disease activity, the natalizumab saturation on CD8+ and CD4+ T cells was <30%. In contrast, the remaining three patients with absence of disease activity had a median natalizumab saturation of 70% (range 59–79%) on CD4+ and 66% (range 52–68%) on CD8+ T cells.
Conclusions
The data of this pilot study indicate that clinical and radiological disease activity is closely linked to natalizumab saturation at the time point of switch. The determination of natalizumab saturation may be an essential tool to monitor cessation of natalizumab treatment.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>24032536</pmid><doi>10.1111/ane.12182</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6314 |
| ispartof | Acta neurologica Scandinavica, 2014-03, Vol.129 (3), p.e12-e15 |
| issn | 0001-6314 1600-0404 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1500761539 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - metabolism biomarker CD4 antigen Female fingolimod Fingolimod Hydrochloride Humans Immunosuppressive Agents - therapeutic use Lymphocytes Magnetic Resonance Imaging Male Medical research Middle Aged Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - pathology Natalizumab natalizumab saturation Propylene Glycols - therapeutic use Sphingosine - analogs & derivatives Sphingosine - therapeutic use Time Factors treatment holiday |
| title | Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T10%3A15%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natalizumab%20saturation:%20biomarker%20for%20individual%20treatment%20holiday%20after%20natalizumab%20withdrawal?&rft.jtitle=Acta%20neurologica%20Scandinavica&rft.au=Wipfler,%20P.&rft.date=2014-03&rft.volume=129&rft.issue=3&rft.spage=e12&rft.epage=e15&rft.pages=e12-e15&rft.issn=0001-6314&rft.eissn=1600-0404&rft.coden=ANRSAS&rft_id=info:doi/10.1111/ane.12182&rft_dat=%3Cproquest_cross%3E3192168921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1491933701&rft_id=info:pmid/24032536&rfr_iscdi=true |